REPL 12.49 (+4%)
US76029N1063BiotechnologyBiotechnology

Replimune Group (REPL) Financial Metrics

This table shows a selected set of financial data points of Replimune Group (REPL). You can choose which elements to display by selecting the desired chart and column.

MarketCap

Total Revenue

Free CashFlow

Year EPS Dividend Yield PE Ratio MarketCap Return On Assets Total Revenue Free CashFlow EBITDA Net Income Cash
2024 -3.24 0 -3.85 831.46M -0.38 0 -191.13M -229.43M -215.79M 74.46M
2023 -2.99 0 -2.82 490.74M -0.31 0 -130.32M -177.4M -174.28M 146.59M
2022 -2.26 0 -12.03 1.42B -0.24 0 -84.52M -114.06M -118.04M 105.95M
2021 -1.75 0 -15.5 1.25B -0.21 0 -63.78M -76.1M -80.87M 182.52M
2020 -1.54 0 -24.84 1.31B -0.27 0 -67.09M -52.6M -52.63M 59.5M
2019 -1.33 0 -10.8 332.9M -0.28 0 -27.98M -22.82M -30.83M 25.7M
2018 -0.92 0 -10.92 215.07M -0.45 0 -16.15M -19.59M -19.7M 17.58M
2017 -0.25 0 0 0 0 0 -7.32M -7.58M -7.7M 20.59M

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.